scispace - formally typeset
Journal ArticleDOI

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.

TLDR
In this paper, the Wee1 inhibitor combined with gemcitabine was evaluated in patients with high-grade serous ovarian cancer, a TP53-mutated tumour type with high replication stress.
About
This article is published in The Lancet.The article was published on 2021-01-23. It has received 98 citations till now. The article focuses on the topics: Gemcitabine & Cancer.

read more

Citations
More filters
Journal ArticleDOI

Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.

TL;DR: The FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system as mentioned in this paper.
Journal ArticleDOI

Targeting replication stress in cancer therapy

TL;DR: Current and emerging approaches for targeting replication stress in cancer, from preclinical and biomarker development to clinical trial evaluation are reviewed.
Journal ArticleDOI

Targeting the replication stress response through synthetic lethal strategies in cancer medicine.

TL;DR: The replication stress response (RSR) involves a downstream kinase cascade comprising ataxia telangiectasia-mutated (ATM), ATM and rad3-related (ATR), checkpoint kinases 1 and 2 (CHK1/2), and WEE1-like protein kinase (WEE1) which cooperate to arrest the cell cycle, protect stalled forks, and allow time for replication fork repair.
Journal ArticleDOI

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

TL;DR: In this paper , the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer were evaluated.
References
More filters
Journal ArticleDOI

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

TL;DR: A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.
Journal ArticleDOI

Integrated genomic analyses of ovarian carcinoma

Debra A. Bell, +285 more
- 30 Jun 2011 - 
TL;DR: It is reported that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1,BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes.
Journal ArticleDOI

Whole-genome characterization of chemoresistant ovarian cancer

Ann-Marie Patch, +99 more
- 28 May 2015 - 
TL;DR: It is shown that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance.
Journal ArticleDOI

Regulation of DNA repair throughout the cell cycle

TL;DR: The repair of DNA lesions that occur endogenously or in response to diverse genotoxic stresses is indispensable for genome integrity and has provided insights into the mechanisms that contribute to DNA repair in specific cell-cycle phases.
Related Papers (5)

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, +116 more
- 28 Oct 2017 - 

Integrated genomic analyses of ovarian carcinoma

Debra A. Bell, +285 more
- 30 Jun 2011 -